Clinical Trial

IMMUNOPLANT for Newly Diagnosed Multiple Myeloma

Study acronym: IMMUNOPLANT
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether Linvoseltamab therapy in patients with newly diagnosed multiple myeloma will convert the disease status from minimal residual disease (MRD)-positive to MRD-negative, and increase the length of time that the disease is controlled. The researchers also want to find out the effects (good and bad) that Linvoseltamab has on participants and the condition.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2024-04-16; most recent amendment 2025-08-11.
Status change: Not Yet Recruiting → Recruiting 2024-09-03
Trial Details
NCT Number NCT06376526
Lead Sponsor Dickran Kazandjian, MD
Collaborators: Regeneron Pharmaceuticals
Conditions Multiple Myeloma
Enrollment 28 participants
Start Date 2024-08-21
Primary Completion 2027-08-31 (estimated)
Study Completion 2029-08-31 (estimated)
Updated on ClinicalTrials.gov 2025-08-14